Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
|Articles|August 3, 2018
Mini Quiz: Borderline Personality Disorder
Author(s)Lois W. Choi-kain, MD
Listen
0:00 / 0:00
Key Takeaways
- Option C reflects that personality disorders, while clinically challenging, are treatable and should not be categorically labeled as untreatable.
- Clinician perceptions of “treatment resistance” can promote therapeutic nihilism and hinder sustained engagement, especially when countertransference is unrecognized.
Do personality disorders get a bad rap? Take the quiz and learn more.
Advertisement
The correct answer is C.
Clinicians often see patients with personality disorders as treatment resistant-and, in some cases, untreatable. While it is true that patients with personality disorders may be challenging to treat, they are treatable.
For more on this topic, see
Advertisement
Related to this article
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
2
Can Digital Memory Tests Detect Tau-Related Cognitive Change Before Alzheimer Disease?
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Preventing Schizophrenia Relapse in Women: What You Need to Know
5